The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

21 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.EBI
Novartis Pharma
Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.EBI
Novartis Institutes For Biomedical Research
Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor.EBI
Universidade Federal Fluminense
Isocoumarins, miraculous natural products blessed with diverse pharmacological activities.EBI
Quaid-I-Azam University
The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.EBI
Campus
Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.EBI
Queensland University Of Technology
Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7.EBI
University Of Montpellier
Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.EBI
Universidade Federal Do Abc
Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.EBI
Universit£
1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.EBI
Universit£
Isomannide derivatives as new class of inhibitors for human kallikrein 7.EBI
Universidade Federal Do Tri£Ngulo Mineiro
Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.EBI
Universidade Federal Do Tri£Ngulo Mineiro
Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors.EBI
Asubio Pharma
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.EBI
German Cancer Research Center (Dkfz)
Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors.EBI
Asubio Pharma
Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium.EBI
University Of Florida
Structure-based drug design to overcome species differences in kallikrein 7 inhibition of 1,3,6-trisubstituted 1,4-diazepan-7-ones.EBI
Asubio Pharma
Design of Potent and Selective Cathepsin G Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold.EBI
The University Of Queensland
Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.BDB
Albert Einstein College Of Medicine
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance.BDB
University Of Cambridge
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.BDB
Parke-Davis Pharmaceutical Research